Christine E. Engeland

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index1.5kcitations71works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(62), CAR-T cell therapy research(40), Cancer Research and Treatments(31), Virology and Viral Diseases(15), Animal Virus Infections Studies(10)

Publications71 total

Enhanced solid tumor cell targeting by a neoepitope-encoding oncolytic measles virus combined with CAR therapy
Molecular Therapy Oncology·2025Open Access
Data from Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
2024Open Access
Supplementary Data from Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
2024Open Access
A new recombinant oncolytic measles virus for therapy of ALL and assessment of its toxicity
Klinische Pädiatrie·2024
Editorial: Rising stars in cancer immunity and immunotherapy 2022
Frontiers in Immunology·2023Open Access
Supplementary Table 1 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 2 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Table 4 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 4 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 1 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Table 3 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 2 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 1 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 4 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Data from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 3 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Figure 3 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Data from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Table 2 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplementary Table 1 from Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Guy Ungerechts(30), Dirk Jäger(20), Christoph Springfeld(12), Christof von Kalle(11), Rūta Veinalde(10), Johannes P.W. Heidbuechel(9), Jean Rommelaere(9), Niels Halama(8), Mathias F. Leber(8), Assia L. Angelova(8), Sascha Bossow(7), Jacek Hajda(7), Ottheinz Krebs(7), Meinhard Kieser(7), Michael Dahm(7), Oliver Sedlaczek(7), Volker Daniel(7), Barbara Leuchs(7), Christian Grossardt(6), Veronika Frehtman(6)